Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Puma Biotechnology reports Q1 revenue of $52.8 million, focuses on NERLYNX sales and in-licensing opportunities

Puma Biotechnology's Q1 2023 earnings call highlighted a focus on improving NERLYNX sales, in-licensing opportunities within the oncology space, and challenges related to patent expiration and regulatory pathways. The company aims to maximize operating cash flows and achieve positive net income while exploring growth opportunities in various cancer settings.

Puma Biotechnology reports stable Q2 revenue, focuses on NERLYNX sales

Puma Biotechnology's Q2 2023 performance reflects stable revenue and a focus on improving NERLYNX sales. The in-licensing of alisertib and the company's financial stability are notable strengths. However, challenges include a decrease in new prescriptions and the need for clear sales and regulatory strategies. Opportunities lie in the extended adjuvant indication, live interactions, and the solid tumor space.

Puma Biotechnology reports stable Q3 revenue, focuses on cost reduction

Puma Biotechnology's Q3 2023 performance reflects stable NERLYNX net revenue but a decrease in prescriptions. The company is focused on cost reduction and evaluating potential in-licensing of drugs. Challenges include maintaining NERLYNX sales growth, while opportunities lie in the development of alisertib for different cancer indications.

Puma Biotechnology reports resilient Q4 earnings amidst NERLYNX challenges

Puma Biotechnology's Q4 2023 performance reflects solid financial results despite challenges in NERLYNX sales. With a strategic focus on clinical trials, net income maintenance, and revenue growth, PBYI aims to capitalize on opportunities in 2024 while addressing key challenges.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

A surprising number of patients discontinued treatment with the company's sole drug product in the first quarter of 2019.

Investors Are Right to Worry About Puma Biotechnology

Puma Biotechnology, Inc. (PBYI) CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript

There are risks to having only one marketed drug product.

Here's Why Puma Biotechnology Fell as Much as 40.7% Today

Puma stock was hammered Friday after sales of breast cancer treatment Nerlynx lagged the Street by north of $20 million despite a first-quarter price hike. Puma also cut its 2019 outlook.

Biotech Hammered On 'Shockingly Poor' Report For Breast Cancer Drug

Shares of small-cap oncology biotech Puma Biotechnology Inc. are sinking to their lowest level since November following the release of its first-quarter results.

Puma Biotech Shares Plunge After Nerlynx Update, Quarterly Report

Puma Biotech (PBYI) incurs narrower loss in Q1. Sales of Nerlynx fall short of expectations due to higher discontinuations.

Puma Biotech (PBYI) Q1 Earnings Top, Nerlynx Disappoints

Shares of Puma Biotechnology Inc. fell nearly 33% Thursday.

Puma Bio down 33% as more patients forgoing treatment with its cancer drug

Investors reacted with dismay over the terms of a license agreement.

Here's Why Puma Biotechnology Fell 17.2% in April

Puma Biotech (PBYI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Puma Biotech (PBYI) to Report a Decline in Earnings: What to Look Out for

Investors apparently did not like the terms of the Nerlynx EU/Africa commercialization deal—specifically the $60M upfront payment and the $345M in potential milestones.

Puma Biotechnology: Investors Didn't Like The EU/Africa Partnership Terms, But The Risk/Reward Is Attractive

The pharma company announced full-year 2018 operating results and multiple business updates.

Here's Why Puma Biotechnology Rose 39.5% in March

Puma Biotech increases cohorts in the phase II SUMMIT basket study on Nerlynx for cancer patients suffering tumors with activating EGFR or HER2 mutations.

Puma Biotech Adds Two Cohorts to Nerlynx Label Expansion Study

Puma Biotech out-licenses development and marketing rights to its breast cancer drug Nerlynx to Pierre Fabre in Europe and across some African countries. Shares fall.

Puma Biotech Out-Licenses Nerlynx Rights in Europe, Stock Down

The terms of a new partnership aren't as good as investors had hoped.

Here's Why Puma Biotechnology Tumbled on Monday

Puma Biotech (PBYI) reported earnings 30 days ago. What's next for the stock?

Why Is Puma Biotech (PBYI) Up 39.5% Since Last Earnings Report?

As of late, it has definitely been a great time to be an investor in Puma Biotechnology.

News for Puma Biotechnology Stock (PBYI)